GSK buying Canada's ID Biomedical for $1.4 billion

09/8/2005 | Bloomberg

In a move to acquire a larger share of the flu vaccine market, GlaxoSmithKline is buying Canada's ID Biomedical in a $1.4 billion deal. GSK's Fluarix flu shot was approved by the U.S. FDA Aug. 31, but the company is expected to produce only 8 million doses this year, and one analyst suggests "capacity issues are what's driving" the move to buy the Canadian biotech firm.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA